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Summary
Background:  The  objective  of  this  study  was  to  report  11  cases  of  malignant  head  and  neck
paraganglioma  and  to  compare  their  epidemiological,  clinical,  and  genetic  characteristics,  their
natural history  and  their  treatment  with  those  of  a  series  of  131  benign  paragangliomas.
Patients  and  methods:  Retrospective  analysis  of  142  patients  with  head  and  neck  paraganglioma
managed between  2001  and  2008.  Age  at  the  time  of  diagnosis,  gender,  primary  tumour  site,
presence of  other  non-head/neck  paragangliomas  and/or  metastases  diagnosed  by  imaging  (CT,
MRI, Octreoscan  or 18F-FDG  PET),  histology,  urinary  catecholamine  and  metanephrine  levels,
family history,  and  genetic  test  results  were  recorded.
Results:  This  series  comprised  131  benign  head  and  neck  paragangliomas,  mostly  observed  in
women with  a  mean  age  at  diagnosis  of  45  years  and  a  predominance  of  tympanojugular  sites
(followed by  carotid  and  vagal  sites)  with  5%  of  secreting  tumours  and  20%  of  multifocal  tumours.
Eleven patients  (7.7%)  with  a  1:1  sex  ratio  presented  criteria  of  malignancy.  These  patients,
with a  lower  mean  age  (38  years),  predominantly  presented  carotid  lesions  with  a  higher  rate
of secreting  and  multifocal  tumours,  27%  and  46%  respectively.  The  main  sites  of  metastases
were bone  and  lymph  nodes.  No  tympanic  paragangliomas  were  observed.
∗ Corresponding author. Service d’otorhinolaryngologie, hôpital Lariboisière (Assistance Publique—Hôpitaux de Paris), 2, rue Ambroise-Paré,
75010 Paris, France.
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Conclusions:  Malignant  paragangliomas  are  mainly  observed  in  young  patients  with  multifocal
tumours,  particularly  carotid  tumours,  and  are  predominantly  related  to  subunit  SDH-B  muta-
tion. The  work-up  in  these  high-risk  patients  must  include  whole  body  scintigraphy  and  spine
MRI. Malignancy  is  not  necessarily  associated  with  a  poor  short-term  prognosis  due  to  the  slow
course of  the  disease.
© 2013  Elsevier  Masson  SAS.  All  rights  reserved.
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he  World  Health  Organisation  [1]  deﬁnes  paragangliomas
PG)  as  neuroendocrine  tumours  arising  from  paraganglia,
ollections  of  neural  crest-derived  paraganglionic  neuroec-
odermal  cells  present  throughout  the  body.
However,  malignant  paragangliomas  are  rare  and  no
onsensus  has  been  reached  concerning  the  histological
riteria  of  malignancy,  although  multiple  mitotic  ﬁgures,
uclear  polymorphism  and  capsular  effraction  may  indicate
he  presence  of  malignancy.  According  to  Lack  [2],  two  of
he  following  three  criteria  are  required  to  conﬁrm  malig-
ancy:  central  necrosis,  vascular  and  lymphatic  invasion  and
itotic  abnormalities.  There  is  a  general  consensus  that
alignancy  is  characterised  by  the  presence  of  metastases,
.e.  paraganglionic  tissue  in  organs  other  than  paraganglia.
his  deﬁnition  can  therefore  be  used  to  distinguish  malig-
ant  tumours  from  multifocal  tumours  arising  in  paraganglia
3].
Limited  data  are  available  in  the  literature  concerning
alignant  head  and  neck  paragangliomas  and  their  natural
istory  is  poorly  deﬁned.  However,  it  is  generally  accepted
hat  6%  to  24%  of  non-adrenal  paraganglia  are  malignant  [4].
ecent  progress  in  molecular  genetics  since  2000  [5]  has  also
evealed  that  SDHx  gene  mutation  is  involved  in  hereditary
araganglia  and  that  malignant  forms  are  often  associated
ith  mutation  of  the  B  subunit  [6].
This  study  reports  11  cases  of  malignant  head  and  neck
G  and  compares  their  epidemiological,  clinical  and  genetic
haracteristics,  natural  history  and  treatment  with  those  of
 series  of  131  benign  PG  managed  over  the  same  period  in
ur  institution.
atients and  methods
his  retrospective  study  concerned  all  patients  consulting
or  a  primary  diagnosis  or  referred  for  head  and  neck  PG  in
ur  university  hospital  between  2001  and  2008.
Age  at  the  time  of  diagnosis,  gender,  primary  tumour
ite,  presence  of  other  non-head/neck  PGs  and/or  metas-
ases  diagnosed  by  imaging,  including  CT,  MRI  or  functional
hole  body  imaging  (somatostatin  scintigraphy, 18FDG  or
23I-MIBG  PET),  sometimes  conﬁrmed  by  histology,  urinary
etanephrine  levels,  family  history,  and  genetic  test  results
ere  recorded.  Patients  were  followed  until  September  2012
r  until  death.esults
his  series  comprised  142  patients,  including  11  (7.7%)
atients  presenting  criteria  of  malignancy.
n
r
i
Patients  with  benign  PG  (group  1)
his  group  comprised  131  patients  (87  females;  M:F  sex
atio:  1:1.98).  The  main  characteristics  of  these  patients
re  shown  in  Table  1.
Mean  age  at  diagnosis  of  the  primary  head  and  neck
G  was  45.3  years  (range:  15—76).  One  hundred  and  thir-
een  (86.3%)  patients  presented  an  isolated  head  and  neck
esion  and  18  (13.7%)  patients  presented  multiple  lesions
synchronous  lesions).  Isolated  lesions  involved  tympanic
n  = 32),  tympanojugular  (n  =  37),  vagal  (n  =  18),  and  carotid
n  = 26)  sites.  Six  patients  (4.6%)  had  secreting  tumours.
Another  head  and  neck  paraganglioma  (metachronous
esions)  was  observed  during  follow-up  in  8  of  the  113
atients  with  a  single  primary  tumour  and  1  para-aortic
G  was  detected  by 111In-pentetreotide  scintigraphy.  The
lobal  multifocal  rate  (including  head  and  neck  and  thoraco-
bdominopelvic  PG)  was  therefore  20.6%  in  group  1.
The  mean  interval  between  diagnosis  of  the  primary
esion  and  recurrence  after  surgery  (n  =  13)  or  diagnosis  of
 new  PG  (n  =  9)  was  9.9  years  (range:  4—20)  and  13  years
range:  2—39),  respectively.
Genetic  testing  (when  available  and  when  accepted  by
he  patient)  was  performed  in  43  patients:  24  patients
55.8%)  presented  a  mutation  of  the  D  subunit  of  the  succi-
ate  dehydrogenase  complex  (SDH-D)  and  4  (9.3%)  presented
 mutation  of  the  SDH-B  subunit;  15  patients  (34.9%)  pre-
ented  no  mutation.
atients  with  malignant  PG  (group  2)
araganglionic  disease
his  group  consisted  of  11  patients  (6  females;  male  to
emale  ratio:  1:1.2).  The  main  patient  characteristics  are
ummarized  in  Table  1. Mean  age  at  the  time  of  diagnosis
as  37.8  years  (range:  17—65).  At  the  time  of  diagno-
is,  paragangliomas  were  isolated  in  9  cases  (82%)  and
ultiple  in  two  cases.  Isolated  tumours  involved  carotid
n  = 5),  vagal  (n  = 2),  tympanojugular  (n  =  1)  and  nasal  cavity
n  = 1)  sites.  The  two  cases  of  multiple  PG  were  tympano-
ugular  and  carotid.  No  pure  tympanic  site  was  observed
n  this  series.  Three  patients  (27.3%)  presented  secreting
umours.
Among  the  9  patients  with  an  isolated  lesion,
etachronous  PG  were  diagnosed  during  follow-up  in  3
ases.  In  these  three  patients,  some  of  these  metachronous
umours  were  situated  in  regions  other  than  the  head  and
eck:  thoracic  (n  =  1),  retroperitoneal  (n  =  1),  thoracic  and
etroperitoneal  (n  =  1).  The  overall  multifocal  rate  (includ-
ng  multiple  head  and  neck  and  thoraco-abdominopelvic
Gs)  was  45.5%.
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Table  1  Characteristics  of  the  two  groups.
Group  1(n  =  131)  Group  2  (n  =  11)
At  the  time  of  diagnosis
Number  of  women  (%)  87  (66)  6  (55)
Number of  secreting  tumours  (%)  6  (4.6)  3  (27.3)
Age at  diagnosis  of  the  ﬁrst  head  and  neck  paraganglioma
(mean  age  (range)  in  years)
45.3  (15—76)  37.8  (17—65)
Site of  paraganglioma
Tympanic  (%) 32  (24.4) 0
Tympanojugular  (%) 37  (28.2) 1  (9)
Vagal nerve  (%) 18  (13.7) 2  (18)
Carotid bulb  (%)  26  (19.8)  5  (55.6)
Other (%)  0  1  nasal  cavity  (9)
Multiple (%)  18  (13.7)  2  (18)
Follow-up
Number of  patients  with  metachronous  lesions  (%) 8  (6) 4  (36)
Number of  PG  in  regions  other  than  the  head  and  neck  (%) 1  (0.8) 3  (27)
Interval between  primary  PG  and  recurrence  (mean  (range)
in years)
9.9  (4—20) 4.5  (1.5—7)
Interval between  primary  tumour  and  second  tumour  (mean
(range)  in  years)
13  (2—39) 5.5  (2—15)
Number of  patients  with  multifocal  tumours  (head  and  neck
PG and  PG  in  other  regions)  (%)
26  (19.8)  5  (45.5)
Genetic testing
SDH-D  mutation  (%)  24  (55.8)  2  (18)
SDH-B mutation  (%)  4  (9.3)  5  (50)
No mutation  (%)  15  (34.9)  3  (27)
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The  mean  interval  between  diagnosis  of  the  primary
lesion  and  recurrence  after  surgery  (n  =  4)  or  diagnosis  of  a
second  PG  (n  =  4)  was  4.5  years  (range:  1.5—7)  and  5.5  years
(range:  2—15),  respectively.
Genetic  testing  was  performed  in  10  patients:  2  patients
presented  a  mutation  of  the  D  subunit  (SDH-D),  5  patients
presented  a  mutation  of  the  B  subunit  (SDH-B)  and  3  patients
had  no  mutation.
Metastases
Metastases  were  present  at  the  time  of  diagnosis  of  the
primary  lesion  in  3  patients  and  were  diagnosed  during
follow-up  in  another  8  patients,  with  a  mean  metastasis-
free  interval  of  8  years  (1—25).  These  metastases  involved
bone  (n  =  7),  cervical  lymph  nodes  (n  =  7),  liver  (n  =  2),  lung
(n  =  1),  and  thyroid  (n  =  1)  (Table  2).
Bone  metastases  were  symptomatic  in  four  cases  and
detected  by  systematic  imaging  in  three  cases.  They  pre-
dominantly  involved  the  spine,  but  also  the  iliac  bone,  ribs,
sternum  or  calvarium.
MRI  demonstrated  two  types  of  lesions:  nodular  and
expanding.  Nodular  lesions  presented  a  speciﬁc  radiolog-
ical  appearance,  as  we  have  previously  described  [7],
consisting  of  a  central  low-intensity  signal  surrounded
by  a  single  fat-like  halo  or  a  double  halo  with  a  fat-
density  inner  circle  and  an  outer  circle  suggestive  of
oedema  (Fig.  1a,  b).  In  some  patients,  these  lesions  coex-
isted  with  expanding  lesions  characterized  by  cortical
m
c
m88  (67)  1  (9)
estruction  and  soft  tissue  involvement,  especially  bone
arrow.
111In-pentetreotide  (Octreoscan)  scintigraphy  revealed
nly  some  of  these  bone  lesions  (Table  2). 123Iodine-labelled
etaiodobenzylguanidine  (123I-MIBG)  scintigraphy  was  per-
ormed  in  4  patients  and  revealed  only  slight  contrast
nhancement  of  the  spine  in  one  patient. 18FDG-PET  was
erformed  in  two  patients  and  was  negative  in  one  case  and
trongly  positive  in  the  other  case.
Cervical  lymph  node  metastases  were  detected  in  7
ases,  either  on  neck  palpation  or  by  imaging  showing  a  mass
ituated  in  a  zone  clearly  distinct  from  the  carotid  bulb  or
ubdigastric  region.
Two  patients  had  nodular  liver  metastases  and  another
atient  had  lung  metastases.  One  patient  had  a  thy-
oid  metastasis,  incorrectly  diagnosed  as  papillary  thyroid
umour  and  treated  by  surgery  and 131Iodine  therapy.  Three
ears  later,  this  patient  developed  vertebral  metastases  and
etrospective  analysis  of  the  thyroid  operative  specimen
stablished  the  correct  diagnosis.
ollow-up
ean  follow-up  was  4.25  years  (range:  1—10.5  years).  One
oreign  patient  died  in  his  country  of  origin  56  months  after
anagement  in  our  institution,  apparently  from  metastatic
achexia.  Two  patients  were  lost  to  follow-up,  one  after  1
onth  and  the  other  after  5  years.
Seven  patients  were  followed  for  vertebral  bone  lesions.
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Table  2  Characteristics  of  metastases  in  11  cases  of  malignant  paraganglioma.
Patient  SDH  mutation  Site  Mode  of
discovery
111In-pentetreotide
scintigraphy
(Octreoscan)
18FDG-PET 123I-MIBG  Spine  MRI  Follow-up
(months)
1  B  Bone,  lymph
nodes
Imaging  Ribs,  sternum  Not  done  Metastases  not
visualized
Multiple  lesions  of
cervical,  thoracic
and  lumbar  spine
96
2 B  Bone  Dorsal  pain  Multiple  lesions  of
cervical,  thoracic  and
lumbar  spine,  sacrum,
occipital  bone
Not  done  Metastases  not
visualized
Multiple  lesions  of
cervical,  thoracic
and  lumbar  spine
Dead  (56)
3 No  mutation  Bone  Weakness  of
lower
limbs  +  pyramidal
syndrome
L3  +  right  clavicle  Not  done  Metastases  not
visualized
Multiple  lesions  of
cervical,  thoracic
and  lumbar  spine
303
4 D  Bone  Imaging  Metastases  not  visualized  Metastases  not
visualized
Not  done  Multiple  lesions  of
cervical,  thoracic
and  lumbar  spine
348
5 B  Lymph  node
bone
Low  back  pain
Palpation
Metastases  not  visualized  Metastases  not
visualized
Not  done  Lesions  of  lumbar
spine
Lost  to
follow-up  at  1
month
6 No  mutation  Bone
Liver
Thyroid
Bone  pain
Imaging
Palpation
Vertebral  column,  ribs,
pelvis,  liver
Vertebrae,
sternum,
sacrum,  pelvis,
ribs
Lesion  of
thoracic  spine
Multiple  lesions  of
cervical,  thoracic
and  lumbar  spine
247
7 B  Lymph  nodes  Palpation  Metastases  not  visualized  Not  done  Not  done  Metastases  not
visualized
250
8 Not  tested  Lymph  nodes  Palpation  Metastases  not  visualized  Not  done  Not  done  Metastases  not
visualized
Lost  to
follow-up  at
144  months
9 B  Lymph  nodes
Bone
Liver
Palpation
Imaging
Thoracic  spine+  liver  Not  done  Not  done  Not  done  21
10 No  mutation  Lymph  nodes  Palpation  Metastases  not  visualized  Not  done  Not  done  Metastases  not
visualized
14
11 D  Lymph  nodes
Lung
Palpation
Imaging
Metastases  not  visualized  Not  done  Not  done  Metastases  not
visualized
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Figure  1  MRI  of  the  lumbar  spine,  sagittal  section,  T1-  (a)  and
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rgadolinium-enhanced  T1-weighted  (b)  sequences:  presence  of
nodular  bone  metastases  with  a  double  halo.
One  patient  (patient  3)  required  surgical  curettage  of  a
lumbar  vertebra  due  to  progressive  lower  limb  paraparesis.
In  ﬁve  patients  (patients  2,  4,  5,  6  and  9),  MRI  after
4  years  did  not  reveal  any  new  lesions  or  any  change  in
the  size  of  the  metastases.  However,  detailed  analysis  of
signal  intensity  on  T1-  and  T2-weighted  sequences  showed
decreased  oedema  of  the  outer  halo  of  two  vertebral  lesions
in  two  patients.
The  last  patient  (patient  1)  was  operated  for  left  vagal
PG  in  2001  and,  two  years  later  presented  a  very  large
left  temporal  lesion  with  intracranial  extension  and  multi-
ple  metastases  of  the  cervicothoracic  vertebrae,  calvarium
and  one  rib.  Radiotherapy  at  a  dose  of  45  Gy  was  delivered
to  the  temporal  lesion  but  bone  metastases  did  not  require
any  treatment,  as  they  remained  asymptomatic.  After  a  long
period  of  apparent  stabilization,  the  patient  consulted  in
November  2012  following  the  appearance  of  two  left  cer-
vical  masses.  CT  and  scintigraphy  conﬁrmed  the  metastatic
nature  of  these  masses,  but  also  revealed  marked  progres-
sion  of  the  C6  and  C7  lesions  (that  initially  had  an  osteolytic
appearance)  associated  with  epiduritis  (Fig.  2).  The  risk  of
short-term  spinal  cord  lesions  justiﬁed  radiotherapy  of  the
vertebral  lesion.  Cervical  lymph  node  dissection  conﬁrmed
the  presence  of  metastases.  This  case  illustrates  the  rela-
tively  slow  rate  of  progression  of  metastatic  disease.
The  7  patients  with  lymph  node  metastases  were  treated
by  neck  dissection  concomitant  with  surgical  treatment  of
the  tympanojugular  or  carotid  tumour  in  6  cases  (patients  5,
7,  8,  9,  10  and  11),  while  the  seventh  patient  corresponded
to  patient  1  described  above.  Two  of  these  6  patients  were
c
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ost  to  follow-up,  one  at  1  month,  and  the  other  at  5
ears.  Three  patients  have  not  developed  any  local  recur-
ence  and  are  currently  alive  with  no  signs  of  progression
f  their  paraganglioma.  The  last  patient  (patient  10),  who
nitially  presented  a  vagal  PG  with  cervical  lymph  node
etastases  treated  by  surgery  and  external  beam  radiothe-
apy,  developed  multiple  bone  and  liver  metastases  during
he  following  year  and  is  currently  in  palliative  care.
Of  the  two  cases  of  liver  metastases  diagnosed  at  the
ime  of  diagnosis  of  the  primary  tumour  (patient  6  and
),  one  also  presented  lung  metastasis  and  died  after  56
onths.  The  other  patient  is  alive  with  no  apparent  signs  of
rogression.
iscussion
his  retrospective,  comparative  study  of  one  of  the  largest
eries  published  to  date  deﬁnes  certain  aspects  of  the  nat-
ral  history  of  malignant  head  and  neck  paraganglioma.
In  line  with  the  literature,  patients  with  benign  head  and
eck  PG  were  predominantly  females  (66%)  and  tumours
ere  predominantly  located  in  tympanojugular  sites  (fol-
owed  by  vagal  and  carotid  sites),  with  a  mean  age  of  45
ears  at  the  time  of  diagnosis,  with  low  rates  of  secreting
nd  multifocal  tumours:  5%  and  20%,  respectively.
In  contrast,  patients  with  malignant  head  and  neck  PG
7.7%  of  the  population  of  this  series,  i.e.  a  comparable
ate  to  that  reported  in  the  literature  [8])  did  not  present
ny  gender  predominance,  mainly  presented  carotid  sites,
ad  a  younger  mean  age  at  the  time  of  diagnosis  (38  years),
nd  presented  high  rates  of  secreting  (27%)  and  multifocal
umours  (46%).  These  characteristics  appear  to  constitute
isk  factors  for  malignancy.
No  purely  tympanic  lesion  was  observed  in  this  series.
hese  forms  are  classically  not  multifocal,  occur  in  the
bsence  of  a  family  history  and  treatment  is  based  on  sur-
ical  resection,  which  is  usually  straightforward.  This  series
onﬁrms  that  pure  tympanic  lesions  are  never  accompanied
y  metastases  [9]  and  therefore  do  not  require  genetic  test-
ng  or  staging  assessment.
Metastatic  spread  may  be  haematogenous  or  lymphatic
nd  mainly  involve  bone  and  lymph  nodes  [4,7,10]. Liver
nd  lung  metastases  are  observed  more  rarely.  Metastases
ay  be  either  synchronous,  at  the  time  of  diagnosis  of  PG,  or
etachronous,  in  which  case  they  appear  to  be  associated
ith  a  better  prognosis  [11].
Bone  metastases  may  remain  asymptomatic  or  may
resent  clinically  in  the  form  of  neurological  deﬁcits  or
ain,  or  radiologically  according  to  two  modalities:  oste-
lytic  and  expanding  or  nodular  surrounded  by  a  single  or
ouble  fat-density  and  water-density  halo.  Reduction  of  the
ater-density  zone  and  increase  of  the  fat-density  zone
ere  observed  during  follow-up,  suggesting  possible  spon-
aneous  involution.  The  results  of  our  series  indicate  the
enerally  slow  rate  of  progression  of  PG.  However,  two
atients  developed  signs  of  extension  to  the  spinal  cord,
equiring  surgery  in  one  case  and  radiotherapy  in  the  other
ase.
Lymph  node  metastases  are  usually  detected  by  neck
alpation  or  by  X-rays  or  scintigraphy.  Tumours  situated
oo  inferiorly  or  too  anteriorly  to  correspond  to  carotid
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Figure  2  a:  neck  MRI,  gadolinium-enhanced  T1-weighted  sequence,  axial  section:  two  left  cervical  lymph  node  metastases;  b:
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wpine MRI,  T2-weighted  sequence,  sagittal  section:  spinal  cor
ptake in  a  lymph  node:  d,  e:  octreoscan,  axial  and  coronal  sec
r  vagal  tumours  must  be  considered  to  be  possible  lymph
ode  metastases.  They  are  sometimes  discovered  on  surgical
xploration  and  are  conﬁrmed  by  histological  examination.
hey  appear  to  be  associated  with  a  relatively  favourable
rognosis,  as  lymph  node  recurrences  appear  to  be  rare.
Functional  imaging  does  not  appear  to  be  a  reliable
odality  for  the  detection  of  bone  metastases.  Although
unctional  imaging  can  detect  primary  PG  of  the  head  and
eck  or  other  sites  with  sensitivity  close  to  100%  [12], 111In-
entetreotide  scintigraphy  failed  to  visualize  all  metastases
n  the  present  series.  This  poor  performance  has  also  been
eported  by  Timmers  et  al.  [13],  who  described  poor  uptake
f 123/131I-MIBG  [14]  by  non-adrenal  PG. 123I-MIBG  revealed
one  metastasis  in  only  one  of  the  four  cases  of  our  series.
PET-CT  has  been  proposed  in  the  literature  for  the  assess-
ent  of  phaeochromocytomas  and  PG. 18F-FDG  is  moreeliable  for  the  detection  of  PG  than  their  metastases
13,15]. 18F-DOPA  has  a  high  sensitivity  for  the  detection  of
enign  head  and  neck  PG  [16],  but  a  low  sensitivity  for  the
etection  of  metastases,  particularly  in  subjects  with  SDH-B
P
i
o
pmpression  over  C7;  c:  octreoscan,  coronal  section:  increased
s:  increased  uptake  of  C7  vertebra.
utation.  The  low  performance  of  these  speciﬁc  agents  can
e  explained  by  loss  of  differentiation  of  metastases  related
o  SDH-B  mutation.
A recent  study  demonstrated  that  plasma  levels  of  a
etabolite  of  dopamine,  methoxytyramine,  higher  than
.2  nmol/L  constituted  a  useful  biomarker  to  detect  the
resence  of  metastases  [17].
In  familial  forms  of  benign  head  and  neck  PG,  a  mutation
f  the  D  subunit  of  the  SDH  gene  is  identiﬁed  in  50%  to  94%
f  cases,  while  a mutation  of  the  B  subunit  is  identiﬁed  in
0%  to  20%  of  cases  [18,19].  In  sporadic  forms,  a  SDH  gene
utation,  mainly  involving  the  D  subunit,  is  reported  in  11%
o  29%  of  cases  [18]. However,  SDH-B  mutations  are  mainly
eported  in  malignant  head  and  neck  PG  [6,8,18,20].  The
esults  of  the  present  series  conﬁrm  these  published  results,
ith  a  predominance  of  SDH-D  mutation  (56%)  in  the  benign
G  group  and  SDH-B  mutation  (5  of  the  10  patients  tested,
.e.  50%)  in  the  malignant  PG  group.  However,  two  patients
f  the  malignant  PG  group  presented  a  SDH-D  mutation,  as
reviously  reported  by  other  authors  [21,22].  No  mutation
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was  identiﬁed  in  the  remaining  3  patients.  Note  that  four
patients  of  the  benign  PG  group  presented  SDH-B  mutation
with  no  signs  malignancy  during  follow-up.
Demonstration  of  an  SDH-B  gene  mutation  in  a  patient
with  head  and  neck  PG  therefore  appears  to  constitute  the
most  relevant  risk  factor  for  malignancy,  justifying  radiologi-
cal  work-up,  especially  when  the  other  risk  factors  described
above  are  also  present:  young  subject,  multiple  sites,  par-
ticularly  carotid,  possibly  secreting,  with  a  family  history  of
PG.
The  free  interval  between  diagnosis  of  the  primary
tumour  and  metastases  can  be  long  and  therefore  justi-
ﬁes  long-term  follow-up,  especially  for  high-risk  patients.
Although  the  5-year  overall  survival  reported  in  the  litera-
ture  for  phaeochromocytomas  and  malignant  PG  ranges  from
40%  to  74%  [5,7,9],  the  individual  prognosis  is  unpredictable.
In  our  study,  all  patients  of  the  malignant  PG  group  (group
2)  were  alive  at  last  follow-up  (with  a  follow-up  of  up  to  29
years),  except  for  one  patient  (with  SDH-B  mutation).  In  a
series  of  5  patients,  Havekes  et  al.  [14]  described  the  case
of  a  patient  who  died  after  a  follow-up  of  32  years:  this
woman  with  SDH-D  mutation  developed  multiple  cervical
lymph  node  and  bone  metastases.
Surgery  is  theoretically  the  only  curative  treatment
for  metastases  of  malignant  PG.  However,  the  treatment
options  for  metastases  depend  on  their  site  and  their  ope-
rability.  Surgery  is  clearly  indicated  in  the  case  of  isolated
or  multiple  lymph  node  metastases,  in  the  neck,  chest
or  abdomen,  especially  as  surgery  also  allows  histological
conﬁrmation  of  malignancy.  Similarly,  isolated  liver  metas-
tases  can  be  treated  by  resection,  sometimes  allowing
long-term  survival.
However,  two-thirds  of  metastases  involve  bone  and  are
usually  vertebral  and  therefore  unresectable.  A  combined
medical  and  surgical  approach  is  indicated  in  these  cases:
analgesics  and  anti-inﬂammatory  drugs  to  control  pain  and
nerve  compression,  but  also  bisphosphonates  and  localized
radiotherapy  or  sometimes  embolization  and  radiofrequency
ablation  [23,24].  Surgical  decompression  followed  by  verte-
broplasty  can  be  proposed  in  the  presence  of  signs  of  spinal
cord  compression.
Another  attractive  treatment  option  is  metabolic  radio-
therapy  based  on  the  property  of  paraganglionic  cells  to
express  somatostatin  receptors  on  their  cell  surface.  This
modality  uses  a  marker  labelled  with  a  highly  radioactive
agent  such  as 131I-MIBG  or 90Ytrium-  or 111Indium-labelled
octreotide.  However,  in  practice,  this  type  of  treatment  is
limited  by  the  fact  that  almost  one-half  of  PG  metastases  do
not  take  up  the  tracer  and  one-third  of  potential  candidates
for  this  therapy  fail  to  respond  [25].  This  treatment  is  also
very  expensive  and  the  results  of  metabolic  radiotherapy  for
metastases  of  tympanojugular  PG  have  not  been  reported
to  date.  The  only  published  studies  concern  metastases  of
phaeochromocytomas  [7,25—27].
Randomized  trials  of  chemotherapy  are  methodologi-
cally  difﬁcult  to  perform,  but  the  addition  of  chemotherapy
appeared  to  provide  improvement  of  symptoms  and  short-
term  remissions  in  some  studies  based  on  small  sample  sizes
[26,27].
Targeted  molecular  therapy  remains  a  promising
approach,  based  on  the  principle  of  the  molecular  effects
of  SDH-B  gene  mutations,  resulting  in  activation  (or
[165
eregulation)  of  genes  targeted  by  hypoxia-induced  fac-
ors.  Targeted  molecular  therapies  are  therefore  designed
o  inhibit  these  genes.  Sunitinib,  an  oral  multi-target
yrosine  kinase  receptor  inhibitor  with  anti-angiogenic  and
ntitumour  activity,  has  been  recently  used  in  some  cases
ith  promising  results  [28].
onclusion
his  retrospective  study  indicates  the  following  conclusions:
 malignant  paragangliomas  are  observed  more  frequently
among  young  patients  with  multifocal  and  secreting
tumours,  particularly,  in  carotid  sites;
 malignant  head  and  neck  paragangliomas  are  mainly  asso-
ciated  with  mutation  of  the  B  subunit  of  the  SDH  gene,  but
a  mutation  of  the  D  subunit  is  sometimes  observed;
 staging  of  high-risk  patients  must  include  spine  MRI,  as
Octreoscan  fails  to  detect  all  metastases;
 pure  tympanic  forms  are  never  malignant  and  do  not  jus-
tify  genetic  testing  or  staging;
 metastases  generally  present  a  low  rate  of  progression
and  are  compatible  with  often  prolonged  survival;
 treatment  of  metastases  must  be  adapted  to  symptoms.
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